Vascular involvement in systemic sclerosis (scleroderma)

References

• HochbergMSilmanASmolenJWeinblattMWeismanMEpidemiology and classification of sclerodermaRheumatology5th edSt. LouisMosby2010
   Google Scholar
• SteenVDMedsgerTAJrSevere organ involvement in systemic sclerosis with diffuse sclerodermaArthritis Rheum200043112437244411083266
   PubMed Web of Science ®Google Scholar
• MayesMDTrojanowskaMGenetic factors in systemic sclerosisArthritis Res Ther20079Suppl 2S517767743
   PubMed Web of Science ®Google Scholar
• AgarwalSKThe genetics of systemic sclerosisDiscov Med2010105113414320807474
   PubMed Web of Science ®Google Scholar
• ArnettFCGourhPSheteSMajor histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controlsAnn Rheum Dis201069582282719596691
   PubMed Web of Science ®Google Scholar
• RodnanGPBenedekTGMedsgerTAJrCammarataRJThe association of progressive systemic sclerosis (scleroderma) with coal miners’ pneumoconiosis and other forms of silicosisAnn Intern Med19676623233344224922
   PubMed Web of Science ®Google Scholar
• RustinMHBullHAZieglerVSilica-associated systemic sclerosis is clinically, serologically and immunologically indistinguishable from idiopathic systemic sclerosisBr J Dermatol199012367257342176091
   PubMed Web of Science ®Google Scholar
• NietertPJSutherlandSESilverRMIs occupational organic solvent exposure a risk factor for scleroderma?Arthritis Rheum1998416111111189627022
   PubMed Web of Science ®Google Scholar
• SilmanAJHowardYHicklinAJBlackCGeographical clustering of scleroderma in south and west LondonBr J Rheumatol199029293962322780
   PubMedGoogle Scholar
• PostlethwaiteAEHarrisLJRazaSHKoduraSAkhigbeTPharmacotherapy of systemic sclerosisExpert Opin Pharmacother201011578980620210685
   PubMed Web of Science ®Google Scholar
• PostlethwaiteAERole of T cells and cytokines in effecting fibrosisInt Rev Immunol1995122–42472587650423
   PubMedGoogle Scholar
• WarringtonKJNairUCarboneLDKangAHPostlethwaiteAECharacterisation of the immune response to type I collagen in sclerodermaArthritis Res Ther200684R13616879746
   PubMed Web of Science ®Google Scholar
• FioccoURosadaMCozziLEarly phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activityAnn Rheum Dis19935242722778484693
   PubMed Web of Science ®Google Scholar
• FreundlichBJimenezSAPhenotype of peripheral blood lymphocytes in patients with progressive systemic sclerosis: activated T lymphocytes and the effect of D-penicillamine therapyClin Exp Immunol19876923753843498592
   PubMed Web of Science ®Google Scholar
• SteenVDEngelEECharleyMRMedsgerTAJrSoluble serum interleukin 2 receptors in patients with systemic sclerosisJ Rheumatol19962346466498730120
   PubMed Web of Science ®Google Scholar
• ParelYAurrand-LionsMSchejaADayerJMRoosnekEChizzoliniCPresence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosisArthritis Rheum200756103459346717907151
   PubMed Web of Science ®Google Scholar
• RadstakeTRvan BonLBroenJIncreased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expressionPLoS One200946e598119543397
   PubMed Web of Science ®Google Scholar
• LiuGBurnsSHuangGThe receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTORNat Immunol200910776977719483717
   PubMed Web of Science ®Google Scholar
• PiconeseSGriGTripodoCMast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiationBlood2009114132639264819643985
   PubMed Web of Science ®Google Scholar
• TokumuraACarboneLDYoshiokaYElevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosisInt J Med Sci20096416817619521548
   PubMed Web of Science ®Google Scholar
• GiacomelliRMatucci-CerinicMCiprianiPCirculating Vdelta1+ T cells are activated and accumulate in the skin of systemic sclerosis patientsArthritis Rheum19984123273349485091
   PubMed Web of Science ®Google Scholar
• SakkasLIPlatsoucasCDIs systemic sclerosis an antigen-driven T cell disease?Arthritis Rheum20045061721173315188347
   PubMed Web of Science ®Google Scholar
• SakkasLIXuBArtlettCMLuSJimenezSAPlatsoucasCDOligoclonal T cell expansion in the skin of patients with systemic sclerosisJ Immunol200216873649365911907131
   PubMed Web of Science ®Google Scholar
• AtamasSPLuzinaIGIngelsJStimulation with type I collagen induces changes in gene expression in peripheral blood mononuclear cells from patients with diffuse cutaneous systemic sclerosis (scleroderma)Clin Exp Immunol2010161342643520529088
   PubMed Web of Science ®Google Scholar
• PostlethwaiteAEWongWKClementsPA multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase diseaseArthritis Rheum20085861810182218512816
   PubMed Web of Science ®Google Scholar
• LafyatisRYorkMInnate immunity and inflammation in systemic sclerosisCurr Opin Rheumatol200921661762219633559
   PubMed Web of Science ®Google Scholar
• FarinaGAYorkMRDi MarzioMPoly(I:C) drives type I IFN-and TGFbeta-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosisJ Invest Dermatol2010130112583259320613770
   PubMed Web of Science ®Google Scholar
• KimDPeckASanterDInduction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosisArthritis Rheum20085872163217318576347
   PubMed Web of Science ®Google Scholar
• WhitfieldMLFinlayDRMurrayJISystemic and cell type-specific gene expression patterns in scleroderma skinProc Natl Acad Sci U S A200310021123191232414530402
   PubMed Web of Science ®Google Scholar
• SatoSFujimotoMHasegawaMTakeharaKAltered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cellsArthritis Rheum20045061918192715188368
   PubMed Web of Science ®Google Scholar
• HasegawaMB lymphocytes: shedding new light on the pathogenesis of systemic sclerosisJ Dermatol201037131020175836
   PubMed Web of Science ®Google Scholar
• KochAEDistlerOVasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosisArthritis Res Ther20079Suppl 2S317767741
   PubMed Web of Science ®Google Scholar
• CalladoMRVianaVSVendraminiMBAutoantibody profile in the experimental model of scleroderma induced by type V human collagenImmunology20071221384617442023
   PubMed Web of Science ®Google Scholar
• BraunRKMartinAShahSInhibition of bleomycin-induced pulmonary fibrosis through pre-treatment with collagen type VJ Heart Lung Transplant201029887388020471860
   PubMed Web of Science ®Google Scholar
• D’AngeloWAFriesJFMasiATShulmanLEPathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controlsAm J Med19694634284405780367
   PubMed Web of Science ®Google Scholar
• BrownGELearyPASkin capillaries in sclerodermaArch Intern Med1925367388
   Google Scholar
• KahalehBVascular disease in scleroderma: mechanisms of vascular injuryRheum Dis Clin North Am20083415771vi18329532
   PubMed Web of Science ®Google Scholar
• CoolCDKennedyDVoelkelNFTuderRMPathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infectionHum Pathol19972844344429104943
   PubMed Web of Science ®Google Scholar
• DorfmullerPHumbertMPerrosFFibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseasesHum Pathol200738689390217376507
   PubMed Web of Science ®Google Scholar
• NagaiYYamanakaMHashimotoCAutopsy case of systemic sclerosis with severe pulmonary hypertensionJ Dermatol2007341176977217973818
   PubMed Web of Science ®Google Scholar
• CannonPJHassarMCaseDBCasarellaWJSommersSCLeRoyECThe relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulationMedicine (Baltimore)19745311464808710
   PubMed Web of Science ®Google Scholar
• HerrickALPathogenesis of Raynaud’s phenomenonRheumatology (Oxford)200544558759615741200
   PubMed Web of Science ®Google Scholar
• TrojanowskaMCellular and molecular aspects of vascular dysfunction in systemic sclerosisNat Rev Rheumatol20106845346020585340
   PubMed Web of Science ®Google Scholar
• CampbellPMLeRoyECPathogenesis of systemic sclerosis: a vascular hypothesisSemin Arthritis Rheum1975443513681135634
   PubMedGoogle Scholar
• MichalowskiRKudejkoJElectron microscopic observations on skeletal muscle in diffuse sclerodermaBr J Dermatol196678124285944482
   PubMed Web of Science ®Google Scholar
• PrescottRJFreemontAJJonesCJHoylandJFieldingPSequential dermal microvascular and perivascular changes in the development of sclerodermaJ Pathol199216632552631517881
   PubMed Web of Science ®Google Scholar
• FleischmajerRPerlishJSShawKVPirozziDJSkin capillary changes in early systemic scleroderma. Electron microscopy and “in vitro” autoradiography with tritiated thymidineArch Dermatol19761121115531557984860
   PubMedGoogle Scholar
• FreemontAJHoylandJFieldingPHodsonNJaysonMIStudies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathyBr J Dermatol199212665615681610706
   PubMed Web of Science ®Google Scholar
• KoenigMJoyalFFritzlerMJAutoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosisArthritis Rheum200858123902391219035499
   PubMed Web of Science ®Google Scholar
• GrassiWCorePCarlinoGBlasettiPCerviniMLabial capillary microscopy in systemic sclerosisAnn Rheum Dis19935285645698215616
   PubMed Web of Science ®Google Scholar
• NortonWLNardoJMVascular disease in progressive systemic sclerosis (scleroderma)Ann Intern Med19707323173244916764
   PubMed Web of Science ®Google Scholar
• FleischmajerRPerlishJSCapillary alterations in sclerodermaJ Am Acad Dermatol1980221611707364973
   PubMed Web of Science ®Google Scholar
• KahalehBMeyerOScorzaRAssessment of vascular involvementClin Exp Rheumatol2003213 Suppl 29S91412889215
   PubMed Web of Science ®Google Scholar
• BlannADIllingworthKJaysonMIMechanisms of endothelial cell damage in systemic sclerosis and Raynaud’s phenomenonJ Rheumatol1993208132513308230013
   PubMed Web of Science ®Google Scholar
• SchachnaLWigleyFMTargeting mediators of vascular injury in sclerodermaCurr Opin Rheumatol200214668669312410092
   PubMed Web of Science ®Google Scholar
• KuwanaMOkazakiYYasuokaHKawakamiYIkedaYDefective vasculogenesis in systemic sclerosisLancet2004364943460361015313361
   PubMed Web of Science ®Google Scholar
• Del PapaNColomboGFracchiollaNCirculating endothelial cells as a marker of ongoing vascular disease in systemic sclerosisArthritis Rheum20045041296130415077314
   PubMed Web of Science ®Google Scholar
• FlemingJNSchwartzSMThe pathology of scleroderma vascular diseaseRheum Dis Clin North Am20083414155vi18329531
   PubMed Web of Science ®Google Scholar
• JimenezSADerkCTFollowing the molecular pathways toward an understanding of the pathogenesis of systemic sclerosisAnn Intern Med20041401375014706971
   PubMed Web of Science ®Google Scholar
• FlemingJNNashRAMcLeodDOCapillary regeneration in scleroderma: stem cell therapy reverses phenotype?PLoS One200831e145218197262
   PubMed Web of Science ®Google Scholar
• SgoncRGruschwitzMSDietrichHRecheisHGershwinMEWickGEndothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human sclerodermaJ Clin Invest19969837857928698871
   PubMed Web of Science ®Google Scholar
• AllanoreYBatteuxFAvouacJAssousNWeillBKahanALevels of circulating endothelial progenitor cells in systemic sclerosisClin Exp Rheumatol2007251606617417992
   PubMed Web of Science ®Google Scholar
• AlbertMLPearceSFFranciscoLMImmature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytesJ Exp Med19981887135913689763615
   PubMed Web of Science ®Google Scholar
• GreenoEWBachRRMoldowCFApoptosis is associated with increased cell surface tissue factor procoagulant activityLab Invest19967522812898765328
   PubMed Web of Science ®Google Scholar
• TsujiSKajiKNagasawaSActivation of the alternative pathway of human complement by apoptotic human umbilical vein endothelial cellsJ Biochem199411647948007883753
   PubMed Web of Science ®Google Scholar
• GargalovicPSGharaviNMClarkMJThe unfolded protein response is an important regulator of inflammatory genes in endothelial cellsArterioscler Thromb Vasc Biol200626112490249616931790
   PubMed Web of Science ®Google Scholar
• LennaSTownsendDMTanFKHLA-B35 upregulates endothelin-1 and downregulates endothelial nitric oxide synthase via endoplasmic reticulum stress response in endothelial cellsJ Immunol201018494654466120335527
   PubMed Web of Science ®Google Scholar
• JainRKMolecular regulation of vessel maturationNat Med20039668569312778167
   PubMed Web of Science ®Google Scholar
• HirschiKKD’AmorePAPericytes in the microvasculatureCardiovasc Res19963246876988915187
   PubMed Web of Science ®Google Scholar
• SundbergCIvarssonMGerdinBRubinKPericytes as collagen-producing cells in excessive dermal scarringLab Invest19967424524668780163
   PubMed Web of Science ®Google Scholar
• RajkumarVSHowellKCsiszarKDentonCPBlackCMAbrahamDJShared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosisArthritis Res Ther200575R1113112316207328
   PubMed Web of Science ®Google Scholar
• RajkumarVSSundbergCAbrahamDJRubinKBlackCMActivation of microvascular pericytes in autoimmune Raynaud’s phenomenon and systemic sclerosisArthritis Rheum199942593094110323448
   PubMed Web of Science ®Google Scholar
• ManzurMGanssRRegulator of G protein signaling 5: a new player in vascular remodelingTrends Cardiovasc Med2009191263019467451
   PubMed Web of Science ®Google Scholar
• HelmboldPFiedlerEFischerMMarschWHyperplasia of dermal microvascular pericytes in sclerodermaJ Cutan Pathol200431643144015186431
   PubMed Web of Science ®Google Scholar
• YanagisawaMKuriharaHKimuraSA novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature198833261634114152451132
   PubMed Web of Science ®Google Scholar
• KahalehMBEndothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic actionArthritis Rheum19913489789831859492
   PubMed Web of Science ®Google Scholar
• YamaneKMiyauchiTSuzukiNSignificance of plasma endothelin-1 levels in patients with systemic sclerosisJ Rheumatol19921910156615711464869
   PubMed Web of Science ®Google Scholar
• VancheeswaranRAzamABlackCDashwoodMRLocalization of endothelin-1 and its binding sites in scleroderma skinJ Rheumatol1994217126812767525957
   PubMed Web of Science ®Google Scholar
• ClozelMSalloukhHRole of endothelin in fibrosis and anti-fibrotic potential of bosentanAnn Med200537121215902842
   PubMed Web of Science ®Google Scholar
• TomitaMFanPSantoroTKahalenBImpaired response to mechanical fluid shear stress (MFSS) by scleroderma microvascular endothelial cells from involved and uninvolved skinArthritis Rheum199740297305
   Google Scholar
• AndersonMEMooreTLHollisSClarkSJaysonMIHerrickALEndothelial-dependent vasodilation is impaired in patients with systemic sclerosis, as assessed by low dose iontophoresisClin Exp Rheumatol200321340312846066
   PubMed Web of Science ®Google Scholar
• BerkBCAbeJIMinWSurapisitchatJYanCEndothelial athero-protective and anti-inflammatory mechanismsAnn N Y Acad Sci200194793109 discussion 109–11111795313
   PubMed Web of Science ®Google Scholar
• DistlerODel RossoAGiacomelliRAngiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcersArthritis Res200246R1112453314
   PubMedGoogle Scholar
• HummersLKHallAWigleyFMSimonsMAbnormalities in the regulators of angiogenesis in patients with sclerodermaJ Rheumatol200936357658219228661
   PubMed Web of Science ®Google Scholar
• DistlerODistlerJHScheidAUncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosisCirc Res200495110911615178641
   PubMed Web of Science ®Google Scholar
• MackiewiczZSukuraAPovilenaiteDIncreased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skinClin Exp Rheumatol200220564164612412194
   PubMed Web of Science ®Google Scholar
• DaviesCAJeziorskaMFreemontAJHerrickALThe differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosisHum Pathol200637219019716426919
   PubMed Web of Science ®Google Scholar
• Mulligan-KehoeMJDrinaneMCMollmarkJAntiangiogenic plasma activity in patients with systemic sclerosisArthritis Rheum200756103448345817907150
   PubMed Web of Science ®Google Scholar
• HanCICampbellGRCampbellJHCirculating bone marrow cells can contribute to neointimal formationJ Vasc Res200138211311911316947
   PubMed Web of Science ®Google Scholar
• TanakaKSataMHirataYNagaiRDiverse contribution of bone marrow cells to neointimal hyperplasia after mechanical vascular injuriesCirc Res200393878379014500338
   PubMed Web of Science ®Google Scholar
• DistlerJHAllanoreYAvouacJEULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cellsAnn Rheum Dis200968216316818653485
   PubMed Web of Science ®Google Scholar
• AvouacJJuinFWipffJCirculating endothelial progenitor cells in systemic sclerosis: association with disease severityAnn Rheum Dis200867101455146018174219
   PubMed Web of Science ®Google Scholar
• KuwanaMKaburakiJOkazakiYYasuokaHKawakamiYIkedaYIncrease in circulating endothelial precursors by atorvastatin in patients with systemic sclerosisArthritis Rheum20065461946195116729283
   PubMed Web of Science ®Google Scholar
• ZhuSEvansSYanBTranscriptional regulation of Bim by FOXO3a and Akt mediates scleroderma serum-induced apoptosis in endothelial progenitor cellsCirculation2008118212156216518981303
   PubMed Web of Science ®Google Scholar
• CiprianiPGuiducciSMiniatiIImpairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosisArthritis Rheum20075661994200417530639
   PubMed Web of Science ®Google Scholar
• Mattuci-CerinicMValentiniGSoranoGGBlood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosisSemin Arthritis Rheum200332528529512701039
   PubMed Web of Science ®Google Scholar
• KahalehMBOsbornILeRoyECIncreased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud’s phenomenonAnn Intern Med1981944 Pt 14824846782927
   PubMed Web of Science ®Google Scholar
• GreavesMMaliaRGMilford WardAElevated von Willebrand factor antigen in systemic sclerosis: relationship to visceral diseaseBr J Rheumatol19882742812853136816
   PubMedGoogle Scholar
• HerrickALIllingworthKBlannAHayCRHollisSJaysonMIVon Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud’s phenomenon and systemic sclerosisAnn Rheum Dis19965521221278712862
   PubMed Web of Science ®Google Scholar
• GoodfieldMJOrchardMARowellNRWhole blood platelet aggregation and coagulation factors in patients with systemic sclerosisBr J Haematol19938446756808217827
   PubMed Web of Science ®Google Scholar
• AmesPRLupoliSAlvesJThe coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndromeBr J Rheumatol19973610104510509374919
   PubMedGoogle Scholar
• FriedhoffLTSeiboldJRKimHCSimesterKSSerotonin induced platelet aggregation in systemic sclerosisClin Exp Rheumatol1984221191236532617
   PubMed Web of Science ®Google Scholar
• PostlethwaiteAEChiangTMPlatelet contributions to the pathogenesis of systemic sclerosisCurr Opin Rheumatol200719657457917917538
   PubMed Web of Science ®Google Scholar
• ChiangTMPostlethwaiteAEA cell model system to study regulation of phosphotidylinositol 3-kinase and protein kinase B activity by cytokines/growth factors produced by type I collagen stimulated immune cells from patients with systemic sclerosisBiochim Biophys Acta2007177081181118617524560
   PubMed Web of Science ®Google Scholar
• PattanaikDPostlethwaiteAEA role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosisDiscov Med2010105116116720807477
   PubMed Web of Science ®Google Scholar
• IgarashiJMichelTSphingosine-1-phosphate and modulation of vascular toneCardiovasc Res200982221222019233865
   PubMed Web of Science ®Google Scholar
• CremersBFleschMKostenisEModulation of myocardial contractility by lysophosphatidic acid (LPA)J Mol Cell Cardiol2003351718012623301
   PubMed Web of Science ®Google Scholar
• ZhangCBakerDLYasudaSLysophosphatidic acid induces neointima formation through PPARgamma activationJ Exp Med2004199676377415007093
   PubMed Web of Science ®Google Scholar
• ChengYMakarovaNTsukaharaRLysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCRCell Signal200921121874188419709640
   PubMed Web of Science ®Google Scholar
• KandabashiTShimokawaHMukaiYInvolvement of rho-kinase in agonists-induced contractions of arteriosclerotic human arteriesArterioscler Thromb Vasc Biol200222224324811834523
   PubMed Web of Science ®Google Scholar
• ChiangTMPostlethwaiteAEAlteration in protein kinase B (AKT) activity in platelets from patients with systemic sclerosisThromb Res2008122450150618355897
   PubMed Web of Science ®Google Scholar
• PitchfordSCMomiSBaglioniSAllergen induces the migration of platelets to lung tissue in allergic asthmaAm J Respir Crit Care Med2008177660461218096710
   PubMed Web of Science ®Google Scholar
• FengDNagyJAPyneKDvorakHFDvorakAMPlatelets exit venules by a transcellular pathway at sites of F-met peptide-induced acute inflammation in guinea pigsInt Arch Allergy Immunol199811631881959693266
   PubMed Web of Science ®Google Scholar
• KravisTCHensonPMAccumulation of platelets at sites of antigenantibody- mediated injury: a possible role for IgE antibody and mast cellsJ Immunol1977118515691573140191
   PubMed Web of Science ®Google Scholar
• AsanoYBujorAMTrojanowskaMThe impact of Fli1 deficiency on the pathogenesis of systemic sclerosisJ Dermatol Sci201059315316220663647
   PubMed Web of Science ®Google Scholar
• Del GaldoFSotgiaFde AlmeidaCJDecreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosisArthritis Rheum20085892854286518759267
   PubMed Web of Science ®Google Scholar
• ZhaoYYLiuYStanRVDefects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout miceProc Natl Acad Sci U S A20029917113751138012177436
   PubMed Web of Science ®Google Scholar
• PatelHHZhangSMurrayFIncreased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertensionFASEB J200721112970297917470567
   PubMed Web of Science ®Google Scholar
• LeRoyECIncreased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblastJ Clin Invest19745448808894430718
   PubMed Web of Science ®Google Scholar
• EckesBMauchCHuppeGKriegTDifferential regulation of transcription and transcript stability of pro-alpha 1(I) collagen and fibronectin in activated fibroblasts derived from patients with systemic sclerodermaBiochem J1996315Pt 25495548615828
   PubMed Web of Science ®Google Scholar
• BrinckmannJNeessCMGaberYDifferent pattern of collagen cross-links in two sclerotic skin diseases: lipodermatosclerosis and circumscribed sclerodermaJ Invest Dermatol2001117226927311511304
   PubMed Web of Science ®Google Scholar
• Van der SlotAJZuurmondAMBardoelAFIdentification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosisJ Biol Chem200327842409674097212881513
   PubMed Web of Science ®Google Scholar
• HunzelmannNBrinckmannJWhat are the new milestones in the pathogenesis of systemic sclerosis?Ann Rheum Dis201069Suppl 1i52i5619995745
   PubMed Web of Science ®Google Scholar
• LoeysBLGerberEERiegert-JohnsonDMutations in fibrillin-1 cause congenital scleroderma: stiff skin syndromeSci Transl Med201022323ra20
   PubMed Web of Science ®Google Scholar
• GardnerHShearstoneJRBandaruRGene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblastsArthritis Rheum20065461961197316736506
   PubMed Web of Science ®Google Scholar
• MilanoAPendergrassSASargentJLMolecular subsets in the gene expression signatures of scleroderma skinPLoS One200837e269618648520
   PubMed Web of Science ®Google Scholar
• IsogaiZOnoRNUshiroSLatent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated proteinJ Biol Chem200327842750275712429738
   PubMed Web of Science ®Google Scholar
• BrinckmannJHunzelmannNKahleBEnhanced fibrillin-2 expression is a general feature of wound healing and sclerosis: potential alteration of cell attachment and storage of TGF-betaLab Invest201090573975220195245
   PubMed Web of Science ®Google Scholar
• VargaJBasheyRIRegulation of connective tissue synthesis in systemic sclerosisInt Rev Immunol1995122–41871997650421
   PubMedGoogle Scholar
• JimenezSASaittaBAlterations in the regulation of expression of the alpha 1(I) collagen gene (COL1A1) in systemic sclerosis (scleroderma)Springer Semin Immunopathol199921439741410945033
   PubMed Web of Science ®Google Scholar
• TrojanowskaMMolecular aspects of sclerodermaFront Biosci20027d608d61811861221
   PubMed Web of Science ®Google Scholar
• RaghowRPostlethwaiteAEKeski-OjaJMosesHLKangAHTransforming growth factor-beta increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblastsJ Clin Invest1987794128512883470308
   PubMed Web of Science ®Google Scholar
• PostlethwaiteAEHolnessMAKataiHRaghowRHuman fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4J Clin Invest1992904147914851401080
   PubMed Web of Science ®Google Scholar
• PostlethwaiteAESeyerJMFibroblast chemotaxis induction by human recombinant interleukin-4. Identification by synthetic peptide analysis of two chemotactic domains residing in amino acid sequences 70–88 and 89–122J Clin Invest1991876214721522040697
   PubMed Web of Science ®Google Scholar
• LeaskAHolmesAAbrahamDJConnective tissue growth factor: a new and important player in the pathogenesis of fibrosisCurr Rheumatol Rep20024213614211890879
   PubMedGoogle Scholar
• SatoSNagaokaTHasegawaMSerum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosisJ Rheumatol200027114915410648031
   PubMed Web of Science ®Google Scholar
• IgarashiANashiroKKikuchiKSignificant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosisJ Invest Dermatol199510522802847636314
   PubMed Web of Science ®Google Scholar
• TourkinaERichardMGoozPAntifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivoAm J Physiol Lung Cell Mol Physiol20082945L84386118203815
   PubMed Web of Science ®Google Scholar
• SeriniGBochaton-PiallatMLRoprazPThe fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1J Cell Biol199814238738819700173
   PubMed Web of Science ®Google Scholar
• HinzBGabbianiGCell-matrix and cell-cell contacts of myofibroblasts: role in connective tissue remodelingThromb Haemost2003906993100214652629
   PubMed Web of Science ®Google Scholar
• KanangatSPostlethwaiteAEHigginsGCHastyKANovel functions of intracellular IL-1ra in human dermal fibroblasts: implications in the pathogenesis of fibrosisJ Invest Dermatol2006126475676516456536
   PubMed Web of Science ®Google Scholar
• HigginsGCWuYPostlethwaiteAEIntracellular IL-1 receptor antagonist is elevated in human dermal fibroblasts that overexpress intracellular precursor IL-1 alphaJ Immunol199916373969397510490999
   PubMed Web of Science ®Google Scholar
• YinZCarboneLDGotohMLysophosphatidic acid-activated Cl- current activity in human systemic sclerosis skin fibroblastsRheumatology (Oxford)201049122290229720823096
   PubMed Web of Science ®Google Scholar
• PradereJPGonzalezJKleinJLysophosphatidic acid and renal fibrosisBiochim Biophys Acta20081781958258718455518
   PubMed Web of Science ®Google Scholar
• PradereJPKleinJGresSLPA1 receptor activation promotes renal interstitial fibrosisJ Am Soc Nephrol200718123110311818003779
   PubMed Web of Science ®Google Scholar
• TangkijvanichPMeltonACChitapanaruxTHanJYeeHFPlatelet-derived growth factor-BB and lysophosphatidic acid distinctly regulate hepatic myofibroblast migration through focal adhesion kinaseExp Cell Res2002281114014712441137
   PubMed Web of Science ®Google Scholar
• WatanabeNIkedaHNakamuraKPlasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severityLife Sci200781121009101517850827
   PubMed Web of Science ®Google Scholar
• TagerAMLaCameraPSheaBSThe lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leakNat Med2008141455418066075
   PubMed Web of Science ®Google Scholar
• IkedaHWatanabeNIshiiISphingosine 1-phosphate regulates regeneration and fibrosis after liver injury via sphingosine 1-phosphate receptor 2J Lipid Res200950355656418955732
   PubMed Web of Science ®Google Scholar
• SwaneyJSMorenoKMGentileAMSabbadiniRAStollerGLSphingosine-1-phosphate (S1P) is a novel fibrotic mediator in the eyeExp Eye Res200887436737518687328
   PubMed Web of Science ®Google Scholar
• Gellings LoweNSwaneyJSMorenoKMSabbadiniRASphingosine-1-phosphate and sphingosine kinase are critical for transforming growth factor-beta-stimulated collagen production by cardiac fibroblastsCardiovasc Res200982230331219228708
   PubMed Web of Science ®Google Scholar
• AdelowoOOOguntonaSScleroderma (systemic sclerosis) among NigeriansClin Rheumatol20092891121112519437086
   PubMed Web of Science ®Google Scholar
• ChowdhurySUMiahMAMahmudMITalukderSIIslamMNIslamNUnusual presentation of progressive systemic sclerosisMymensingh Med J200817219219618626457
   PubMedGoogle Scholar
• RadstakeTRvan BonLBroenJThe pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypesPLoS One200946e590319536281
   PubMed Web of Science ®Google Scholar
• LiaoJJHuangMCGoetzlEJCutting edge: Alternative signaling of Th17 cell development by sphingosine 1-phosphateJ Immunol200717895425542817442922
   PubMed Web of Science ®Google Scholar
• GabrielliAAvvedimentoEVKriegTSclerodermaN Engl J Med2009360191989200319420368
   PubMed Web of Science ®Google Scholar
• MartinSTesseAHugelBShed membrane particles from T lymphocytes impair endothelial function and regulate endothelial protein expressionCirculation2004109131653165915023873
   PubMed Web of Science ®Google Scholar
• Abou-RayaAAbou-RayaSHelmiiMStatins: potentially useful in therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcersJ Rheumatol20083591801180818709692
   PubMed Web of Science ®Google Scholar
• Matucci-CerinicMSeiboldJRDigital ulcers and outcomes assessment in sclerodermaRheumatology (Oxford)200847Suppl 5v46v4718784143
   PubMed Web of Science ®Google Scholar
• DhillonSBosentan: a review of its use in the management of digital ulcers associated with systemic sclerosisDrugs200969142005202419747014
   PubMed Web of Science ®Google Scholar
• PopeJEThe diagnosis and treatment of Raynaud’s phenomenon: a practical approachDrugs200767451752517352512
   PubMed Web of Science ®Google Scholar
• ThompsonAEPopeJECalcium channel blockers for primary Raynaud’s phenomenon: a meta-analysisRheumatology (Oxford)200544214515015546967
   PubMed Web of Science ®Google Scholar
• BakstRMerolaJFFranksAGJrSanchezMRaynaud’s phenomenon: pathogenesis and managementJ Am Acad Dermatol200859463365318656283
   PubMed Web of Science ®Google Scholar
• FeuersteinGWilletteRAiyarNClinical perspectives of calcitonin gene related peptide pharmacologyCan J Physiol Pharmacol1995737107010748846403
   PubMed Web of Science ®Google Scholar
• FonsecaCAbrahamDPonticosMNeuronal regulators and vascular dysfunction in Raynaud’s phenomenon and systemic sclerosisCurr Vasc Pharmacol200971343919149638
   PubMed Web of Science ®Google Scholar
• BunkerCBReavleyCO’ShaughnessyDJDowdPMCalcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud’s phenomenonLancet1993342886380838100913
   PubMed Web of Science ®Google Scholar
• BunkerCBGoldsmithPCLeslieTAHayesNForemanJCDowdPMCalcitonin gene-related peptide, endothelin-1, the cutaneous microvasculature and Raynaud’s phenomenonBr J Dermatol199613433994068731660
   PubMed Web of Science ®Google Scholar
• DooleyAGaoBBradleyNAbnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginineRheumatology (Oxford)200645667668416399843
   PubMed Web of Science ®Google Scholar
• KhanFBelchJJSkin blood flow in patients with systemic sclerosis and Raynaud’s phenomenon: effects of oral L-arginine supplementationJ Rheumatol199926112389239410555898
   PubMed Web of Science ®Google Scholar
• TehLSManningJMooreTTullyMPO’ReillyDJaysonMISustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud’s phenomenonBr J Rheumatol19953476366417670782
   PubMedGoogle Scholar
• FranksAGJrTopical glyceryl trinitrate as adjunctive treatment in Raynaud’s diseaseLancet19821826376776119495
   PubMed Web of Science ®Google Scholar
• ChungLShapiroLFiorentinoDMQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon: a randomized, controlled trialArthritis Rheum200960387087719248104
   PubMed Web of Science ®Google Scholar
• LeightonCDrug treatment of sclerodermaDrugs200161341942711293650
   PubMed Web of Science ®Google Scholar
• WigleyFMKornJHCsukaMEOral iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind studyArthritis Rheum19984146706779550476
   PubMed Web of Science ®Google Scholar
• PopeJFenlonDThompsonAIloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosisCochrane Database Syst Rev20002CD00095310796395
   PubMedGoogle Scholar
• Della BellaSMolteniMMocellinCFumagalliSBonaraPScorzaRNovel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion moleculesProstaglandins2001652–3738311377584
   PubMed Web of Science ®Google Scholar
• KawaldABurmesterGRHuscherDSunderkotterCRiemekastenGLow versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud’s phenomenon and systemic sclerosis: a randomized, open, single-center studyJ Rheumatol20083591830183718634152
   PubMed Web of Science ®Google Scholar
• RehbergerPBeckheinrich-MrowkaPHausteinUFSticherlingMProstacyclin analogue iloprost influences endothelial cell-associated soluble adhesion molecules and growth factors in patients with systemic sclerosis: a time course study of serum concentrationsActa Derm Venereol200989324524919479119
   PubMed Web of Science ®Google Scholar
• ErreGLPassiuGAntioxidant effect of Iloprost: current knowledge and therapeutic implications for systemic sclerosisReumatismo2009612909719633795
   PubMedGoogle Scholar
• ChungLFiorentinoDDigital ulcers in patients with systemic sclerosisAutoimmun Rev20065212512816431342
   PubMed Web of Science ®Google Scholar
• HummersLKWigleyFMManagement of Raynaud’s phenomenon and digital ischemic lesions in sclerodermaRheum Dis Clin North Am200329229331312841296
   PubMed Web of Science ®Google Scholar
• FriesRShariatKvon WilmowskyHBohmMSildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapyCirculation2005112192980298516275885
   PubMed Web of Science ®Google Scholar
• KumarNGriffithsBAllenJThermographic and symptomatic effect of a single dose of sildenafil citrate on Raynaud’s phenomenon in patients with systemic sclerosis: a potential treatmentJ Rheumatol20063391918191916960964
   PubMed Web of Science ®Google Scholar
• BruecknerCSBeckerMOKroenckeTEffect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot studyAnn Rheum Dis20106981475147819900936
   PubMed Web of Science ®Google Scholar
• De LaVegaAJDerkCTPhosphodiesterase-5 inhibitors for the treatment of Raynaud’s: a novel indicationExpert Opin Investig Drugs20091812329
   PubMed Web of Science ®Google Scholar
• RosatoEBorgheseFPisarriSSalsanoFThe treatment with N-acetylcysteine of Raynaud’s phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patientsClin Rheumatol200928121379138419690939
   PubMed Web of Science ®Google Scholar
• KornJHMayesMMatucci CerinicMDigital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonistArthritis Rheum200450123985399315593188
   PubMed Web of Science ®Google Scholar
• BredemeierMA higher degree of criticism about the effectiveness of bosentan for digital ulcers in scleroderma patients, as for interstitial disease, is also necessary: Comment on the article by Seibold et alArthritis Rheum2010623128312920597113
   PubMed Web of Science ®Google Scholar
• Matucci-CerinicMDentonCPFurstDEBosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trialAnn Rheum Dis2011701323820805294
   PubMed Web of Science ®Google Scholar
• LaunayDDiotEPasquierEBosentan for treatment of active digital ulcers in patients with systemic sclerosisPresse Med2006354 Pt 158759216614599
   PubMed Web of Science ®Google Scholar
• Garcia de la Pena-LefebvrePRodriguez RubioSValero ExpositoMLong-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patientsRheumatology (Oxford)200847446446618263597
   PubMed Web of Science ®Google Scholar
• IannoneFRiccardiMTGuiducciSBosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertensionAnn Rheum Dis20086781121112618029384
   PubMed Web of Science ®Google Scholar
• GholamPSehrTEnkAHartmannMSuccessful treatment of systemic-sclerosis- related digital ulcers with a selective endothelin type A receptor antagonist (sitaxentan)Dermatology2009219217117319590168
   PubMed Web of Science ®Google Scholar
• DziadzioMDentonCPSmithRLosartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trialArthritis Rheum199942122646265510616013
   PubMed Web of Science ®Google Scholar
• GliddonAEDoreCJBlackCMPrevention of vascular damage in scleroderma and autoimmune Raynaud’s phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinaprilArthritis Rheum200756113837384617968938
   PubMed Web of Science ®Google Scholar
• PopeJFenlonDThompsonAPrazosin for Raynaud’s phenomenon in progressive systemic sclerosisCochrane Database Syst Rev20002CD00095610796398
   PubMedGoogle Scholar
• WiseRAWigleyFMWhiteBEfficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover studyArthritis Rheum200450123994400115593189
   PubMed Web of Science ®Google Scholar
• BaileySREidAHMitraSFlavahanSFlavahanNARho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocationCirc Res200494101367137415087420
   PubMed Web of Science ®Google Scholar
• BoinFWigleyFMUnderstanding, assessing and treating Raynaud’s phenomenonCurr Opin Rheumatol200517675276016224254
   PubMed Web of Science ®Google Scholar
• FurspanPBChatterjeeSMayesMDFreedmanRRCooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud’s phenomenonRheumatology (Oxford)200544448849415695304
   PubMed Web of Science ®Google Scholar
• FurspanPBChatterjeeSFreedmanRRIncreased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud’s diseaseArthritis Rheum20045051578158515146428
   PubMed Web of Science ®Google Scholar
• Lyseng-WilliamsonKJarvisBImatinibDrugs2001611217651774 discussion 1775–176611693465
   PubMed Web of Science ®Google Scholar
• Ramos-CasalsMFonollosa-PlaVBrito-ZeronPSiso-AlmirallATargeted therapy for systemic sclerosis: how close are we?Nat Rev Rheumatol56526927820386562
   PubMed Web of Science ®Google Scholar
• DistlerJHDistlerOIntracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosisRheumatology (Oxford)10200847Supplv10v1118784126
   PubMed Web of Science ®Google Scholar
• FurukawaSYasudaSAmengualOHoritaTAtsumiTKoikeTProtective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot studyAnn Rheum Dis20066581118112016837498
   PubMed Web of Science ®Google Scholar
• KuwanaMOkazakiYKaburakiJLong-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosisMod Rheumatol200919553053519590932
   PubMed Web of Science ®Google Scholar
• SamboPAmicoDGiacomelliRIntravenous N-acetylcysteine for treatment of Raynaud’s phenomenon secondary to systemic sclerosis: a pilot studyJ Rheumatol200128102257226211669166
   PubMed Web of Science ®Google Scholar
• KhannaDDiagnosis and management of systemic sclerosisIndian J Rheumatol201056975
   Google Scholar
• LeeSSharmaKThe pathogenesis of fibrosis and renal disease in scleroderma: recent insights from glomerulosclerosisCurr Rheumatol Rep20046214114815016345
   PubMedGoogle Scholar
• KobayashiHNishimakiTKaiseSSuzukiTWatanabeKKasukawaRImmunohistological study endothelin-1 and endothelin- A and B receptors in two patients with scleroderma renal crisisClin Rheumatol199918542542710524561
   PubMed Web of Science ®Google Scholar
• PennHHowieAJKingdonEJScleroderma renal crisis: patient characteristics and long-term outcomesQJM2007100848549417601770
   PubMed Web of Science ®Google Scholar
• SteenVDMedsgerTAJrLong-term outcomes of scleroderma renal crisisAnn Intern Med2000133860060311033587
   PubMed Web of Science ®Google Scholar
• SteenVDCostantinoJPShapiroAPMedsgerTAJrOutcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitorsAnn Intern Med199011353523572382917
   PubMed Web of Science ®Google Scholar
• BeckettVLDonadioJVJrBrennanLAJrUse of captopril as early therapy for renal scleroderma: a prospective studyMayo Clin Proc198560117637713903366
   PubMed Web of Science ®Google Scholar
• BleyerAJDonaldsonLAMcIntoshMAdamsPLRelationship between underlying renal disease and renal transplantation outcomeAm J Kidney Dis20013761152116111382683
   PubMed Web of Science ®Google Scholar
• ChangYJSpieraHRenal transplantation in sclerodermaMedicine (Baltimore)199978638238510575420
   PubMed Web of Science ®Google Scholar
• PhamPTPhamPCDanovitchGMPredictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literatureAm J Transplant20055102565256916162209
   PubMed Web of Science ®Google Scholar
• GibneyEMParikhCRJaniAFischerMJCollierDWisemanACKidney transplantation for systemic sclerosis improves survival and may modulate disease activityAm J Transplant20044122027203115575905
   PubMed Web of Science ®Google Scholar
• StupiAMSteenVDOwensGRBarnesELRodnanGPMedsgerTAJrPulmonary hypertension in the CREST syndrome variant of systemic sclerosisArthritis Rheum19862945155243707629
   PubMed Web of Science ®Google Scholar
• HachullaELaunayDMouthonLIs pulmonary arterial hypertension really a late complication of systemic sclerosis?Chest200913651211121919429720
   PubMed Web of Science ®Google Scholar
• BadeschDBTapsonVFMcGoonMDContinuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trialAnn Intern Med2000132642543410733441
   PubMed Web of Science ®Google Scholar
• Kowal-BieleckaOLandeweRAvouacJEULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)Ann Rheum Dis200968562062819147617
   PubMed Web of Science ®Google Scholar
• BarstRJGalieNNaeijeRLong-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinilEur Respir J20062861195120316899485
   PubMed Web of Science ®Google Scholar
• OudizRJSchilzRJBarstRJTreprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue diseaseChest2004126242042715302727
   PubMed Web of Science ®Google Scholar
• OlschewskiHSimonneauGGalieNInhaled iloprost for severe pulmonary hypertensionN Engl J Med2002347532232912151469
   PubMed Web of Science ®Google Scholar
• ChannickRNSimonneauGSitbonOEffects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled studyLancet200135892881119112311597664
   PubMed Web of Science ®Google Scholar
• RubinLJBadeschDBBarstRJBosentan therapy for pulmonary arterial hypertensionN Engl J Med20023461289690311907289
   PubMed Web of Science ®Google Scholar
• McLaughlinVVSurvival in patients with pulmonary arterial hypertension treated with first-line bosentanEur J Clin Invest200636Suppl 3101516919005
   PubMed Web of Science ®Google Scholar
• WilliamsMHDasCHandlerCESystemic sclerosis associated pulmonary hypertension: improved survival in the current eraHeart200692792693216339813
   PubMed Web of Science ®Google Scholar
• BarstRJLanglebenDFrostASitaxsentan therapy for pulmonary arterial hypertensionAm J Respir Crit Care Med2004169444144714630619
   PubMed Web of Science ®Google Scholar
• BarstRJLanglebenDBadeschDTreatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentanJ Am Coll Cardiol200647102049205616697324
   PubMed Web of Science ®Google Scholar
• GalieNBrundageBHGhofraniHATadalafil therapy for pulmonary arterial hypertensionCirculation2009119222894290319470885
   PubMed Web of Science ®Google Scholar
• GirgisREFrostAEHillNSSelective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue diseaseAnn Rheum Dis200766111467147217472992
   PubMed Web of Science ®Google Scholar
• HumbertMThe burden of pulmonary hypertensionEur Respir J20073011217601966
   PubMed Web of Science ®Google Scholar
• BadeschDBHillNSBurgessGSildenafil for pulmonary arterial hypertension associated with connective tissue diseaseJ Rheumatol200734122417242217985403
   PubMed Web of Science ®Google Scholar
• GhofraniHASeegerWGrimmingerFImatinib for the treatment of pulmonary arterial hypertensionN Engl J Med2005353131412141316192491
   PubMed Web of Science ®Google Scholar
• PattersonKCWeissmannAAhmadiTFarberHWImatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertensionAnn Intern Med2006145215215316847299
   PubMed Web of Science ®Google Scholar
• PerrosFMontaniDDorfmullerPPlatelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertensionAm J Respir Crit Care Med20081781818818420966
   PubMed Web of Science ®Google Scholar
• SchermulyRTDonyEGhofraniHAReversal of experimental pulmonary hypertension by PDGF inhibitionJ Clin Invest2005115102811282116200212
   PubMed Web of Science ®Google Scholar
• AsanoYFuture treatments in systemic sclerosisJ Dermatol2010371547020175840
   PubMed Web of Science ®Google Scholar
• EddahibiSGuignabertCBarlier-MurAMCross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasiaCirculation2006113151857186416606791
   PubMed Web of Science ®Google Scholar
• MarcosEAdnotSPhamMHSerotonin transporter inhibitors protect against hypoxic pulmonary hypertensionAm J Respir Crit Care Med2003168448749312773327
   PubMed Web of Science ®Google Scholar